S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:BCRX

BioCryst Pharmaceuticals Competitors

$10.92
-0.95 (-8.00 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.78
Now: $10.92
$12.01
50-Day Range
$8.15
MA: $9.92
$11.98
52-Week Range
$1.58
Now: $10.92
$12.90
Volume8.17 million shs
Average Volume7.17 million shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.03

Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying BCRX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to BioCryst Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares BioCryst Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Amgen29.42%95.55%15.52%

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Amgen$23.36 billion5.49$7.84 billion$14.8214.97

Amgen has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Amgen0111402.56

BioCryst Pharmaceuticals presently has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Amgen has a consensus price target of $257.3043, suggesting a potential upside of 15.95%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than BioCryst Pharmaceuticals.

Summary

Amgen beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares BioCryst Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Gilead Sciences5.48%37.77%12.76%

Analyst Ratings

This is a summary of current ratings and recommmendations for BioCryst Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Gilead Sciences1111202.46

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than BioCryst Pharmaceuticals.

Institutional & Insider Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Gilead Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Gilead Sciences$22.45 billion3.54$5.39 billion$6.1410.30

Gilead Sciences has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and BioCryst Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042212.89
BioCryst Pharmaceuticals03802.73

Vertex Pharmaceuticals currently has a consensus price target of $292.68, indicating a potential upside of 40.85%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion12.98$1.18 billion$4.2948.44
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62

Vertex Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats BioCryst Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Regeneron Pharmaceuticals061512.77

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, indicating a potential upside of 4.17%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 39.26%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Regeneron Pharmaceuticals$7.86 billion6.12$2.12 billion$21.4720.93

Regeneron Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Insider and Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats BioCryst Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Biogen and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151202.22
BioCryst Pharmaceuticals03802.73

Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 15.52%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than BioCryst Pharmaceuticals.

Volatility & Risk

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.79$5.89 billion$33.577.85
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62

Biogen has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Institutional and Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biogen beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BioCryst Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Alexion Pharmaceuticals$4.99 billion6.54$2.40 billion$9.7415.24

Alexion Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioCryst Pharmaceuticals has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BioCryst Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Alexion Pharmaceuticals017712.36

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares BioCryst Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 15 factors compared between the two stocks.


BioCryst Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$221.91-0.9%$128.17 billion$23.36 billion17.90Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$63.23-0.8%$79.45 billion$22.45 billion65.19Analyst Downgrade
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$207.79-0.3%$54.02 billion$4.16 billion26.24
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$449.38-0.6%$48.14 billion$7.86 billion16.42
Biogen logo
BIIB
Biogen
1.9$263.57-1.1%$40.15 billion$14.38 billion8.72
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$148.46-0.2%$32.64 billion$4.99 billion34.69Unusual Options Activity
News Coverage
Seagen logo
SGEN
Seagen
1.7$145.45-1.7%$26.35 billion$916.71 million57.26Insider Selling
Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$121.02-4.6%$20.46 billion$876.29 million-54.76Analyst Upgrade
Insider Selling
Incyte logo
INCY
Incyte
1.9$77.50-1.9%$17.04 billion$2.16 billion-49.36
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.37-5.1%$16.07 billion$219.75 million-17.54
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$76.35-0.3%$13.88 billion$1.70 billion17.47Analyst Revision
Novavax logo
NVAX
Novavax
1.6$158.10-16.1%$10.06 billion$18.66 million-30.29Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
Repligen logo
RGEN
Repligen
1.7$183.21-9.1%$10.03 billion$270.24 million223.43Analyst Report
Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.97-2.2%$8.73 billion$788.10 million99.97Unusual Options Activity
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.27-3.0%$7.22 billion$1.12 billion106.81Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.34-1.8%$7.14 billion$1.45 billion15.17
Exelixis logo
EXEL
Exelixis
1.9$21.31-0.1%$6.65 billion$967.78 million44.40Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.41-3.8%$5.47 billion$195.99 million252.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$90.87-4.2%$4.84 billion$1.11 billion29.22Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$71.51-2.4%$4.31 billion$806.43 million-10.13Analyst Report
High Trading Volume
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.21-9.0%$3.98 billion$36.13 million-85.39Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Up
Alkermes logo
ALKS
Alkermes
1.4$18.21-2.4%$2.90 billion$1.17 billion-39.59Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.19-3.1%$2.81 billion$901.90 million-23.28
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.35-3.0%$2.74 billion$182.24 million-9.00Earnings Announcement
Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.71-4.3%$2.35 billion$120.28 million-143.14Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.43-1.2%$2.14 billion$638.60 million-10.93Analyst Report
Decrease in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.08-0.0%$1.80 billionN/A-10.12Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.36-3.9%$1.67 billion$82.27 million-20.39
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$9.99-0.2%$1.61 billion$428.41 million14.48Insider Buying
Codexis logo
CDXS
Codexis
1.5$20.01-4.2%$1.19 billion$68.46 million-57.17Analyst Upgrade
Innoviva logo
INVA
Innoviva
1.4$11.06-0.1%$1.12 billion$261.02 million5.64
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$25.20-5.2%$997.09 million$3.57 million-11.30Gap Up
BOLT
Bolt Biotherapeutics
1.6$28.78-11.8%$993.54 millionN/A0.00Analyst Report
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$17.49-2.3%$959.90 million$227.19 million48.58Insider Selling
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.47-0.2%$959.28 million$35.22 million-6.18
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.31-8.6%$923.59 million$150,000.00-6.16Analyst Downgrade
MannKind logo
MNKD
MannKind
1.4$3.38-7.1%$835.39 million$63.04 million-16.09Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.66-7.8%$807.09 million$322.07 million-6.34Upcoming Earnings
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.33-7.3%$638.20 million$252 million-1.98Analyst Report
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-7.0%$604.95 million$59.29 million-23.87Earnings Announcement
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.66-1.9%$591.64 million$143.01 million-1.08
Geron logo
GERN
Geron
1.4$1.77-4.0%$549.54 million$460,000.00-5.06Upcoming Earnings
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.43-4.0%$521.13 million$22.27 million-5.11Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.20-2.5%$466.95 million$109.33 million-2.35
XOMA logo
XOMA
XOMA
1.8$35.35-2.3%$389.63 million$18.37 million-31.85Upcoming Earnings
Decrease in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.13-11.4%$386.99 million$36.63 million-4.86Analyst Upgrade
High Trading Volume
Verastem logo
VSTM
Verastem
1.5$2.22-2.7%$376.90 million$17.46 million-1.57Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.